单克隆抗体对膀胱肿瘤性质与预后的评估价值  

Clinical study of monoclonal antibodies in bladder tumors

作　　者：霍红旭[1] 杨书文[1] 李景东[1] 蔡文清[1] 黎伟[1] 蔡广增[1] 黑兰荪[1] 

机构地区：[1]河北医学院第二附属医院泌尿外科,050000

出　　处：《临床泌尿外科杂志》1994年第6期360-362,共3页Journal of Clinical Urology

摘　　要：采用一组单克隆抗体（T16、M344、T138、T43）,以 APAAP免疫细胞化学方法,对83例膀胱移行细胞癌的95份及10例非肿瘤患者的10份膀胱冲洗液或肿瘤切除标本作了研究。T16在全部105份标本呈阳性。随着肿瘤分期、分级的升高,M344阳性率逐渐降低,T138及T43阳性牢逐渐升高。在肿瘤复发组和进展组,T138及T43的阳性率明显高于肿瘤无复发组。结果表明:M344、T138及T43单克隆抗体所针对的肿瘤抗原的阳性表达与肿瘤的分期、分级及预后密切相关,可作为膀胱肿瘤恶性程度、复发及浸润进展的估价指标。Using a panel of four monoclonal antibodies (T16,M344,T138,T43),an immunocy-tochemical(APAAP) study of bladder washings and tumor tissues was carried out in 95 specimens from 83 transitional cell carcinoma and 10 of non-tumor patients. T16 was positive in all of 105 specimens. With the elevation of stage and grade of blader tumor,the positive rate of M344 wasd decreased and T138 or T43 was increased. In relapsed and progressed patients,the positive rate of T138 or T43 was clearly higher than that of primary tumor. The results indicate that the positivty of M344,T138 and T43 was closely ralated with stage ,grade and prognosis. It can be used as evaluating marker of malighant degree,recurrence and progression of bladder tumors.

关 键 词：移行上皮细胞癌 单克隆抗体 膀胱肿瘤 预后 

分 类 号：R737.140.7[医药卫生—肿瘤]